General MedicationsCAPSULEGeneric
OZANIMOD
OZANIMOD
Standard Dose
0.23MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary
Approval overview OZANIMOD is listed in Drugs@FDA under application 219236 (ANDA).
Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient OZANIMOD Form and strength CAPSULE - 0.23MG Sponsor SYNTHON BV Submission history Latest submission status date: 2025-07-22 00:00:00.
Structured Monograph
Clinical summary
Approval overview OZANIMOD is listed in Drugs@FDA under application 219236 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient OZANIMOD Form and strength CAPSULE - 0.23MG Sponsor SYNTHON BV Submission history Latest submission status date: 2025-07-22 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: None (Tentative Approval)
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.